Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
25 hedge funds and large institutions have $15M invested in Regulus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 2 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
3.73% more ownership
Funds ownership: 52.23% → 55.97% (+3.7%)
0% more capital invested
Capital invested by funds: $15M → $15M (+$51.7K)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.04M |
| 2 |
VF
Virtu Financial
New York
|
+$37.6K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$17K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.3K |
| 5 |
Renaissance Technologies
New York
|
+$5.8K |
Top Sellers
| 1 |
LPL Financial
San Diego,
California
|
-$27.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.15K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.64K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$580 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$183 | -126 | -61% |
|
RGLS Hedge Fund Activity: Q3 2023 in Review
25 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2023, worth a combined $15M — up 0.35% from $15M a quarter earlier.
Fund positioning in RGLS was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 7 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.04M. The largest seller was LPL Financial, exiting entirely with an estimated $27.2K sold.
- 25 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $15M of Regulus Therapeutics stock for Q3 2023, up 0.35% quarter-over-quarter.
- 2 funds opened new Regulus Therapeutics positions in Q3 2023 and 2 closed out, a net change of 0 holders.
- The largest Regulus Therapeutics buyer in Q3 2023 was Fidelity Investments, an estimated $1.04M added.
- The largest Regulus Therapeutics seller in Q3 2023 was LPL Financial, an estimated $27.2K sold.
Based on aggregated 13F filings for Q3 2023.